RxDoctor Payments Data

Salim Lakhani, MD

Internal Medicine · Houston, TXNPI 1972530939

Payments from drug & device makers

$375in general payments, 2019–2025

Across 18 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$126
  • Novartis$76
  • Novo Nordisk$38
  • Bayer$28
  • Pfizer$24
  • AstraZeneca$22
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$375100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$375 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$70,124
Medicare patients
91
Services billed
953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol95$126,204
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$107,794
OzempicSemaglutide101$98,909
JardianceEmpagliflozin55$55,407
EliquisApixaban33$33,360
JanuviaSitagliptin Phosphate19$31,235
XareltoRivaroxaban24$30,690
Tresiba Flextouch U-200Insulin Degludec26$27,580
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$16,123
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$15,570
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$12,024
SymbicortBudesonide/Formoterol Fumarate16$7,053
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$6,752
Albuterol Sulfate HfaAlbuterol Sulfate159$6,086
Novolog FlexpenInsulin Aspart27$5,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$22$145,281126 claims
GSKTrelegy Ellipta, Anoro Ellipta$126$123,917147 claims
Novo NordiskOzempic$38$98,909101 claims
PfizerEliquis$24$33,36033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →